Kyorin Pharmaceutical Co (TSE:4569) Cash And Cash Equivalents : 円14,017 Mil (As of Sep. 2024)

View and export this data going back to 2001. Start your Free Trial

What is Kyorin Pharmaceutical Co Cash And Cash Equivalents?

Kyorin Pharmaceutical Co's quarterly cash and cash equivalents declined from Mar. 2024 (円13,886.00 Mil) to Jun. 2024 (円0.00 Mil) but then increased from Jun. 2024 (円0.00 Mil) to Sep. 2024 (円14,017.00 Mil).

Kyorin Pharmaceutical Co's annual cash and cash equivalents declined from Mar. 2022 (円26,994.00 Mil) to Mar. 2023 (円19,394.00 Mil) and declined from Mar. 2023 (円19,394.00 Mil) to Mar. 2024 (円13,886.00 Mil).

Kyorin Pharmaceutical Co Cash And Cash Equivalents Historical Data

The historical data trend for Kyorin Pharmaceutical Co's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kyorin Pharmaceutical Co Cash And Cash Equivalents Chart

Kyorin Pharmaceutical Co Annual Data

Trend

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Cash And Cash Equivalents

Get a 7-Day Free Trial

31,925.00

27,445.00

26,994.00

19,394.00

13,886.00

Kyorin Pharmaceutical Co Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Cash And Cash Equivalents	Get a 7-Day Free Trial															26,232.00	19,149.00	13,886.00	-	14,017.00

Kyorin Pharmaceutical Co Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Kyorin Pharmaceutical Co (TSE:4569) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.

Kyorin Pharmaceutical Co Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of Kyorin Pharmaceutical Co's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.

Kyorin Pharmaceutical Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Kyorin Pharmaceutical Co Ltd (TSE:4569) » Definitions » Cash And Cash Equivalents

Comparable Companies

Traded in Other Exchanges

KYRNF:USA

Address

6, Kanda Surugadai 4-chome, Chiyoda-ku, Tokyo, JPN, 101-8311

Website

https://www.kyorin-pharm.co.jp

Kyorin Pharmaceutical Co Ltd is engaged in manufacturing and sale of pharmaceutical products. The company manages its business in two reportable segments namely Pharmaceutical Business and the Consumer Healthcare (Skincare) Business. The Pharmaceutical business focuses on producing and selling ethical drugs, generic drugs and over-the-counter drugs. The Consumer Healthcare (Skincare) Business mainly sells and purchases skincare products. The company's products include Kipres, for treating bronchial asthma and allergic rhinitis; Mucodyne, a mucoregulant; Pentasa, for treating ulcerative colitis and Crohn's disease; and Uritos, for treating overactive bladder. Majority of the company's revenue comes from domestic sales.

Kyorin Pharmaceutical Co Headlines

No Headlines